Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - SQZ Biotechnologies Co | sqz-ex322_6.htm |
| EX-31.2 - EX-31.2 - SQZ Biotechnologies Co | sqz-ex312_9.htm |
| EX-31.1 - EX-31.1 - SQZ Biotechnologies Co | sqz-ex311_8.htm |
| EX-23 - EX-23.1 CONSENT - SQZ Biotechnologies Co | sqz-ex23_2950.htm |
| EX-4 - EX-4.3 DESCRIPTION OF CAPITAL STOCK - SQZ Biotechnologies Co | sqz-ex4_1628.htm |
| 10-K - 10-K - SQZ Biotechnologies Co | sqz-10k_20201231.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of SQZ Biotechnologies Company (the “Company”) for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: March 18, 2021 |
|
By: |
/s/ Armon Sharei, Ph.D. |
|
|
|
|
Armon Sharei, Ph.D. |
|
|
|
|
Chief Executive Officer (principal executive officer) |